T h e ne w e ngl a nd jou r na l o f m e dicine A sthma is a common chronic inflammatory disease of the airways that is characterized by variable airway obstruction, hypersecretion of mucus, airway inflammation, and hyperresponsiveness of the airways. The dysregulation of innate and adaptive immune responses is considered to play a central role in the development of the disease. The high degree of interindividual heterogeneity identified in different patient populations has led to the definition of several clinical phenotypes and pathophysiological endotypes. 1 The allergic response driven by the type 2 helper T cell (Th2), 2,3 also termed the Th2 molecular endotype, is thought to be characteristic of allergic asthma. 4, 5 Approximately half the patients with asthma, regardless of the severity of the disease, exhibit this Th2 endotype. The endotype is characterized by a predominant activation of Th2 cells that produce cytokines such as interleukins 4, 5, and 13. The expression and production of all these Th2 cytokines have been shown in isolated cell systems and invertebrates to be controlled by the zinc finger transcription factor GATA3, which is essential for Th2-cell differentiation and activation and is considered to be the master transcription factor of the Th2 pathway of immune activation. 6 The overexpression of GATA3 has been observed in specimens from bronchoalveolar lavage and lung biopsies obtained from patients with severe asthma, even when they are receiving intensive therapy. 7 Thus, interventions that can disrupt this immune network -including treatments targeting components downstream of the transcription factor GATA3 -are being developed for the treatment of asthma. 8 Since GATA3 is expressed only in intracellular processes, we developed a GATA3-specific DNA enzyme (DNAzyme) with in vivo cell-penetrating capabilities. DNAzymes are catalytically active, single-stranded, synthetic DNA antisense molecules that do not occur in nature. The DNAzyme hgd40 -the active drug product in SB010consists of 34 bases. Nine bases each at the 3′ and 5′ region form two binding domains that are highly specific for binding the target messenger RNA (mRNA) of GATA3. The central core of the molecule represents the catalytic domain that accounts for the cleavage of the target after the binding of hgd40 to GATA3 mRNA 9,10 ( Fig. S1 and S2 in the Supplementary Appendix, available with the full text of this article at NEJM.org). The hgd40 enzyme has shown efficacy in preclinical mod-els of allergic airway inflammation and has significantly reduced levels of both GATA3 mRNA and protein and, subsequently, the production of Th2 cytokines in human T cells and tissue explants 11, 12 (Fig. S3 in the Supplementary Appendix). Since unwanted, off-target effects have not been noted 13, 14 and since no major safety concerns were identified in three recently completed randomized, placebo-controlled, dose-escalation phase 1 trials, 15 we conducted this phase 2a trial to assess the efficacy of SB010.
Me thods

Study Design and Oversight
We conducted this randomized, double-blind, placebo-controlled trial between January 2013 (first patient enrolled) and October 2013 (last visit by last patient) at seven sites in Germany that specialize in respiratory research. After patient screening and baseline assessments were performed, participants were assigned to receive active treatment or placebo for 4 weeks. Randomization was performed at Inamed with the use of a centrally generated list and with no stratification. Details of the study design are shown in Figure 1 and the protocol (available with the statistical analysis plan at NEJM.org). The trial was approved by the German regulatory agency Bundesinstitut für Arzneimittel und Medizinprodukte, by a central ethics committee, and by the local ethics committee at each participating site and was conducted according to the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All participants provided written informed consent before any study-specific procedures were performed. Data were collected at each study site and entered into a database at Inamed. The statistical analysis was performed independently by FGK Clinical Research. The first draft of the manuscript was prepared by the first and last authors. A professional medical writer funded by Sterna Biologicals provided writing and editorial support. The first and last authors and the authors employed by the sponsor vouch for the accuracy and completeness of the data, the statistical analysis, and the fidelity of the trial to the final protocol.
Patients
We recruited white male patients between 18 and 64 years of age who had received a diagnosis of mild asthma, according to criteria in the guide-lines from the Global Initiative for Asthma, 16 at least 6 months before screening and who had not received treatment with any asthma medication other than inhaled short-acting bronchodilators. If a patient had been receiving treatment with inhaled glucocorticoids, the medications were stopped at least 2 weeks before the screening visit. At the screening visit, the forced expiratory volume in 1 second (FEV 1 ) had to be 70% or more of the predicted normal value for at least 6 hours after any use of a short-acting bronchodilator. The allergic nature of the asthma had to be confirmed by means of a positive response to common aeroallergens on a skin-prick test and an allergeninduced decline in FEV 1 of 20% or more in the early asthmatic response and 15% or more in the late asthmatic response. The presence of sputum eosinophils (at least 1 in 400 counted cells) had to be confirmed either before or after the allergen challenge conducted at screening. The full details of the criteria for study inclusion and exclusion are provided in the protocol.
Treatment
The active product in SB010 is the GATA3-specific DNAzyme hgd40 (BioSpring); sequencing details for hgd40 are shown in Figure S4 in the Supplementary Appendix. The final drug product and the placebo were prepared at one site in identical packaging by BAG Health Care. Patients received 10 mg of SB010 in 2 ml of phosphate-buffered saline or matching placebo once daily for 28 consecutive days; both study drugs were administered in the morning by means of flow-and volume-controlled inhalation for a duration of 3 to 8 minutes with the use of an Akita 2 Apixneb nebulizer (Activaero). 17 Patients administered the active treatment or placebo at a study site under the supervision of the study staff on days 1, 7, 13, Panel A shows an overview of the study design and procedures. Panel B summarizes screening and randomization. In the SB010 group, 21 patients completed all the study assessments; 1 patient was not eligible for evaluation because the dose of allergen administered in the pretreatment allergen challenge (AC) differed from that administered in the post-treatment AC. In the placebo group, 19 patients completed all the study assessments; 2 patients were not eligible for evaluation (1 patient required treatment with a short-acting beta-agonist during the AC, and 1 patient was administered a dose in the pretreatment AC that differed from the dose administered in the post-treatment AC). In the placebo group, the data for late asthmatic response (LAR) were missing for 1 patient because serial spirometry was unintentionally stopped 4 hours after allergen provocation. Fe NO denotes the fraction of nitric oxide in exhaled air, FEV 1 forced expiratory volume in 1 second, IS induced sputum, MCh methacholine challenge, and R randomization. T h e ne w e ngl a nd jou r na l o f m e dicine 20, 26, and 28. On the remaining days, the product was self-administered by the study patients, who had been trained to inhale from the device (with a placebo inhalant) at the screening visit.
Procedures
After a safe starting concentration had been identified, 18 increasing concentrations of inhaled aeroallergen were administered at the screening visit to determine the inhaled-aeroallergen regimen that would be used during the treatment phase. 19 Inhaled-allergen challenges were administered in the identical manner before randomization (pretreatment) and after the 28-day study period (posttreatment). 20 Serial spirometric measurements were performed repeatedly in accordance with recent guidelines. 21 Appropriate washout times between challenges were implemented. An overview of the main study procedures and the interventions is shown in Figure 1A (a full summary of study procedures can be found in the study protocol).
Assessments
A methacholine challenge was used to assess airway responsiveness at the times indicated in Figure 1A . Responsiveness was determined on the basis of the provocative concentration of methacholine required to reduce the FEV 1 by at least 20% (methacholine PC 20 ). The challenges were conducted in accordance with the guidelines of the American Thoracic Society (ATS). 22 Levels of fractional exhaled nitric oxide (Fe NO ) were measured at the times indicated in Figure 1A with the use of a hand-held device (NIOX MINO, Aerocrine) in accordance with the recommendations of the ATS and the European Respiratory Society 23 and the manufacturer's instructions. Induced sputum samples were obtained at five time points ( Fig. 1A) : at screening, up to 2 weeks before the pretreatment challenge, 24 hours after the pretreatment challenge, 24 to 48 hours before the post-treatment challenge, and 24 hours after the post-treatment challenge. Assessment of cell distribution and analysis of mediators in the supernatant were performed at a central laboratory. 24 Cytokines and chemokines were measured with a type 1 helper T-cell (Th1) and Th2 assay and a chemokine multiplex assay. The tryptase level in sputum supernatants was measured with the use of an enzyme-linked immunosorbent assay.
Adverse events and any medications prescribed in relation to such an event were assessed at every visit with the use of open questions. Laboratory analyses (e.g., measurement of hematologic and clinical chemistry values and urinalysis) were performed before the first administration of SB010 or placebo and at 2-week intervals during the study period.
Outcome Measures
The primary outcome measure was the area under the curve (AUC) for FEV 1 , expressed as a percentage of the baseline FEV 1 during late asthmatic response (4 to 7 hours after allergen challenge), after administration of multiple doses of inhaled SB010. Secondary outcomes were the safety and side-effect profile of SB010, as assessed by evaluation of adverse events, vital signs, electrocardiographic findings, laboratory analyses, and tests of pulmonary function. Exploratory end points included the AUC for FEV 1 during early asthmatic response (0 to 3 hours after allergen challenge), allergen-induced changes in airway responsiveness (methacholine PC 20 ) , and changes in Fe NO and in biomarker levels in plasma and sputum after treatment with SB010.
Statistical Analysis
We calculated that for the study to have at least 80% power to detect a between-group difference in effect size of 8% for the change in the AUC during the late-phase asthmatic response (percent change in FEV 1 × no. of hours), a sample of at least 38 participants who could be evaluated would be required, assuming a probability of type I error of 10%. On the basis of an anticipated dropout rate of 15%, 43 patients were randomly assigned to receive SB010 or placebo. Efficacy and pharmacodynamic outcomes were analyzed for all patients who could be evaluated (intention-to-treat population), as indicated in Figure 1 . The primary efficacy outcome (AUC for late asthmatic response) was compared between treatment groups with the use of an analysis-of-covariance (ANCOVA) model, with the baseline AUC in the late asthmatic response used as the covariate. The calculation of the AUC was based on the percentage of baseline FEV 1 over time with the use of the trapezoidal rule, as detailed in the statistical analysis plan in the protocol. Four patients in the SB010 group and three patients in the placebo group had a late asthmatic response only in the first pretreatment allergen challenge.
For these patients, data on lung function from this challenge were used as the pretreatment value; for all other patients, the baseline value was the re-sponse to the second allergen challenge performed immediately before treatment. Other end points were also analyzed with the use of the same 
R esult s
Patients
In the SB010 group, 21 patients completed all the study assessments; in the placebo group, 18 completed the assessment of late asthmatic response and 19 completed the assessment of early asthmatic response (Fig. 1B) . The demographic and baseline data for these patients are shown in Table S2 in the Supplementary Appendix.
Late-and Early-Phase Responses
As shown in Figure 2 (and Tables S3 and S4 in the Supplementary Appendix), the late asthmatic response was attenuated after treatment with SB010, and there was a significant improvement (i.e., decrease) in the mean AUC from the pretreatment to the post-treatment allergen challenge, from 66.4 to 44.0 (percent FEV 1 × hours × 100), reflecting a decrease of 33.7% (as compared with a worsening [i.e., increase] of 1.4% in the placebo group) (P = 0.02), and an improvement (i.e., decrease) in the maximum decline in FEV 1 from 30.1% to 20.6%, reflecting a decrease of 31.6% (P = 0.09). The early asthmatic response was also attenuated, with a significant improvement in the mean AUC from 37.9 to 33.6, reflecting a mean improvement in the AUC of 11.3% (as compared with a worsening of 10.5% in the placebo group) (P = 0.03), and an improvement in the maximum decline in FEV 1 from 30.3% to 23.8%, reflecting a decrease of 21.5% (P = 0.04) ( Fig. 2, and Tables S3 and S4 in the Supplementary Appendix). Data for individual patients are listed in the Tables S5A and S5B in the Supplementary Appendix
Interference with Markers of Th2-Driven Inflammation
After 28 days of treatment, SB010 attenuated the allergen-induced increase in sputum eosinophilia as compared with placebo, although this difference was not significant (P = 0.06) There was, however, a significant change in levels of blood interleukin-5 (P = 0.05) (Fig. 3) . The post-treatment increase in interleukin-5 levels observed in the placebo group was not observed in the group receiving SB010. At the end of the 28-day study period, sputum tryptase levels were significantly lower in the SB010 group than in the placebo group (median, 6.39 ng per milliliter [interquartile range, 2.03 to 13.88] vs. median, 13.10 ng per milliliter [interquartile range, 6.05 to 22.77]; P = 0.05). Allergen-induced levels of Fe NO and airway hyperresponsiveness to methacholine remained unaffected by either SB010 or placebo 24 hours after the challenge ( Table S8 in the Supplementary Appendix).
Safety and Adverse Events
No noteworthy differences in adverse events were observed between patients receiving SB010 and those receiving placebo during the 28-day study period. Eight patients in the placebo group, as compared with six patients in the SB010 group, had an adverse event (Table 1 ). There were no serious adverse events during the study period. Shown are the changes in plasma levels of interleukin-5 after an allergen challenge between the time of initiation of the study drug and the completion of the 28-day study period among patients who had detectable plasma levels of interleukin-5 at either time point or at both time points. Symbols represent the same individual patients in the SB010 and placebo groups as shown in Figure 2 . The thick black lines represent the mean values. The P value is for the between-group difference in the change in values. The analysis of safety end points did not reveal any safety concerns. There were no significant between-group differences in pretreatment and posttreatment levels of TNF-α, interleukins 1β and 8, monocyte chemotactic proteins 1 and 4, macrophage inflammatory protein 1β, macrophagederived chemokine, and interferon-inducible protein 10 ( Table S7 in the Supplementary Appendix). No significant increases in levels of rheumatoid factor or antinuclear antibodies were detected in either group.
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Discussion
The inhaled bronchial allergen challenge is a widely accepted in vivo model for the observation of allergic inflammation and bronchoconstriction. 19, 25 All new therapeutic approaches targeting pathways of Th2 cytokines, such as interleukin-4, 26-28 interleukin-5, [29] [30] [31] interleukin-13, 32,33 and thymic stromal lymphopoietin (TSLP), 34 which are now in later stages of development, were successful in attenuating the late asthmatic response in early clinical trials. In this study, treatment with SB010 significantly improved lung function during both early and late asthmatic responses after allergen inhalation. Since SB010 specifically and selectively targets the transcription factor GATA3, these data strongly support the importance of GATA3-dependent and regulated pathways in the asthmatic response after allergen inhalation in patients with a phenotype for Th2-driven asthma. 6 The patients in our study had mild allergic asthma with a typical Th2-driven endotype, as indicated by elevated levels of eosinophils in blood and sputum and elevated levels of Fe NO . 35, 36 This type-2 endotype not only is present in prototypical atopic and allergic asthma but also has recently been observed in other clinical phenotypes of asthma, including hypereosinophilic late-onset asthma, persistent and severe asthma, and aspirin-sensitive asthma. 5, 37, 38 The criteria for inclusion in the study were designed to cover a broad spectrum of patients with this endotype (e.g., requiring only the "presence of sputum eosinophils"), and the data on lung function showed that SB010 had a significant effect in this population. SB010 had a more pronounced attenuating effect on the late asthmatic response, but there was also significant attenuation in the early asthmatic response. This dual mode of action across both phases of the asthmatic response has been reported for anti-IgE 39 and anti-TSLP 34 but not inhaled glucocorticoids. 40 The central role of GATA3 in the regulation of the Th2 response is well established. Both the T h e ne w e ngl a nd jou r na l o f m e dicine development and the maintenance of Th2-effector functions have been shown to depend strictly on GATA3. 41 More recently, investigators have identified an essential function of GATA3 in type 2 innate lymphoid cells. 42 However, this transcription factor also has important functions that extend well beyond its effects on the Th2-cell subset. GATA3 is also expressed in mast cells, 41 eosinophils, 43 and airway epithelial cells, where it controls type 2 cytokine expression and effector mechanisms associated with the allergen-induced allergic response. 44, 45 After an allergen challenge, the early asthmatic response depends on mast-cell degranulation, whereas the late asthmatic response is considered to be preferentially T-cell dependent and accompanied by a marked influx of eosinophils into the airways and the airway lumen. Mast-cell tryptase represents a reliable and robust marker of mast-cell activation and mast-cell degranulation. Our results indicate that SB010 directly or indirectly affects these effector cells of the asthmatic response after allergen inhalation. It is likely that SB010 performs this inhibitory and modulatory function in a dual fashion, both by modulating Th2 cells, and thus depriving effector cells of survival and activation factors, and by directly interfering with GATA3 mRNA in eosinophils and mast-cells in the local inflamed tissue. Additional mechanistic studies are needed to further elucidate the biologic effects of treatment with a GATA3-specific DNAzyme. In our small study, one patient in the SB010 group had nausea and one had pruritus. Our database is too small to draw any conclusions about the long-term safety of this treatment, especially in regard to infectious events.
In conclusion, this proof-of-concept trial showed that treatment with the inhaled DNAzyme in SB010 significantly attenuated both the early-phase and late-phase asthmatic responses after allergen provocation. Further clinical studies are warranted to explore the question of whether these effects translate into clinical benefits in patients who have symptomatic, persistent asthma with a predominant Th2 phenotype.
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